Todas las noticias

Spineway informs its shareholders that they are invited to attend the Combined General Meeting to be heldon Monday, March 25, 2024 at 16:00 p.m. at the Group's headquarters, 7 allée Moulin Berger in Ecully (69).

The Board of Directors of Spineway, meeting on February 6, 2024 under the chairmanship of Stéphane Le Roux, approved the financial statements for the year ended December 31, 2023.

Spineway recorded revenue of €10.5 million in 2023, an increase of 42% compared with 2022. This growth was driven by the strong sales performance of Distimp products and the consolidation of revenue from Spine Innovations, acquired in July 2022.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that it has decided to carry out a reverse split of its share capital on the basis of 1 new share for 2,000 old shares.

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces the accelerated rollout of its range of VEOS implants for intervertebral fixation by posterior approach into new markets.

An Extraordinary General Mee1ng of Spineway shareholders was held on first no1ce on Friday, November 10, 2023 at 9:30 a.m. at the company’s registered office, 7 allée Moulin Berger in Ecully (69)

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces the appointment of Sandrine Carle as Deputy Chief Executive Officer. Ms. Carle joined Spineway in July 2022, at the time of the acquisition of Spine Innovations, where she was CEO. She was instrumental in the successful integration of Spine Innovations into the Spineway Group.

Spineway Group, specialists in innovative implants for the treatment of severe spinal pathologies, is pleased to announce that its VEOS posterior spinal fixation system received an excellent response from the spine implant industry at the North American Spine Society (NASS) Congress in Los Angeles last October1.

Spineway Group, a specialist in innovative implants for the treatment of severe spinal conditions, is pleased to announce the recent 510(k) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System.